Brincidofovir

Brincidofovir
Clinical data
Trade namesTembexa
Other namesCMX001; Cidofovir-HDP; hexadecyloxypropyl-cidofovir
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
  • ({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)[3-(hexadecyloxy)propoxy]phosphinic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H52N3O7P
Molar mass561.701 g·mol−1
3D model (JSmol)
  • CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](CO)Cn1ccc(N)nc1=O
  • InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1
  • Key:WXJFKKQWPMNTIM-VWLOTQADSA-N

Brincidofovir, sold under the brand name Tembexa, is an antiviral drug used to treat smallpox. Brincidofovir is a prodrug of cidofovir.[4] Conjugated to a lipid, the compound is designed to release cidofovir intracellularly, allowing for higher intracellular and lower plasma concentrations of cidofovir, effectively increasing its activity against dsDNA viruses, as well as oral bioavailability.[5]

The most common side effects include diarrhea, nausea, vomiting, and abdominal pain.[3] It carries an FDA-mandated black box warning of an increased risk of death with extended use.[6][7] Brincidofovir was approved for medical use in the United States in June 2021.

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  2. ^ "Regulatory Decision Summary for Tembexa". Drug and Health Products Portal. 11 December 2023. Retrieved 2 April 2024.
  3. ^ a b "FDA approves drug to treat smallpox". U.S. Food and Drug Administration (FDA). 4 June 2021. Archived from the original on 8 June 2021. Retrieved 7 June 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ Cite error: The named reference Chimerix was invoked but never defined (see the help page).
  5. ^ Florescu DF, Keck MA (October 2014). "Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses". Expert Review of Anti-Infective Therapy. 12 (10): 1171–1178. doi:10.1586/14787210.2014.948847. PMID 25120093. S2CID 25854860.
  6. ^ "FDA Tembexa Product Insert" (PDF).
  7. ^ "DailyMed - TEMBEXA- brincidofovir tablet, film coated". dailymed.nlm.nih.gov.